FAGRON N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.76 EUR | +0.68% |
|
+0.91% | +6.92% |
| Apr. 11 | Transcript : Fagron NV, Q1 2024 Sales/ Trading Statement Call, Apr 11, 2024 | |
| Apr. 11 | Fagron Reports Revenue Results for the First Quarter Ended 31 March 2024 | CI |
ETFs positioned on Fagron N.V.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.80% | 22 M€ | -1.21% | ||
| 0.01% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 1 M€ | -.--% | - | |
| 0.00% | 29 M€ | -3.53% | - | |
| 0.00% | 152 M€ | -3.56% | - | |
| 0.00% | 26 M€ | -4.70% | - |
Fagron N.V. specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. The group ensures the sale of pharmaceutical formulas and raw materials, provides third-party pharmaceutical compounding services to pharmacists and hospitals, etc.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.76
EUR
Average target price
21.7
EUR
Spread / Average Target
+22.18%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.92% | 1.38B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- FAGR Stock
- Funds and ETFs Fagron N.V.
